Mapping of a protective helper T cell epitope of human influenza A virus hemagglutinin

Biochemical and Biophysical Research Communications

Volumn 270, Issue 1, 2000, Pages 190-198

  Gogolák, Péter ^a   Simon, Ágnes ^a   Horváth, Attila ^a   Réthi, Bence ^a   Simon, István ^b   Berkics, Katalin ^c   Rajnavölgyi, Éva ^a   Tóth, Gábor K ^c  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b INSTITUTE OF ENZYMOLOGY   (Hungary)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EPITOPE MAPPING; HELPER CELL; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALIA; INFLUENZA A VIRUS; INFLUENZA VIRUS;

EID: 0034595110     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.2384     Document Type: Article

References (29)

1. Murali-Krishna K., Altman J. D., Suresh M., Sourdive D. J. D., Zajac A. J., Miller J. D., Slansky J., Ahmed R. Counting antigen-specific CD8 T cells: A re-evaluation of bystander activation during viral infection. Immunity. 8:1998;177-187.
2. Zajac A. J., Murali-Krishna K., Blattman J. N., Ahmed R. Therapeutic vaccination against chronic viral infection: The importance of cooperation between CD4+ and CD8+ T cells. Curr. Opin. Immunol. 10:1998;444-449.
3. Chicz R. M., Urban R. G., Lane W. S., Gorga J. C., Stern L. J., Vignali D. A. A., Strominger J. L. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature. 358:1992;764-768.
4. Rammensee H. G., Friede T., Stevanovic S. MHC ligands and peptide motifs: First listing. Immunogenetics. 41:1995;178-228.
5. Jardetzky T. S., Gorga J. C., Busch R., Rothbard J., Strominger J. L., Wiley D. C. Peptide binding to HLA-DR1: A peptide with most residues substituted to alanine retains MHC binding. EMBO J. 9:1990;1797-1803.
6. Hill C. M., Liu A., Marshall K. W., Mayer J., Jorgensen B., Yuan B., Cubbon R. M., Nichols E. A., Wicker L. S., Rothbard J. B. Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. J. Immunol. 152:1994;2890-2898.
7. Stern L. J., Brown J. H., Jardetzky T. S., Gorga J. C., Urban R. G., Strominger J. L., Wiley D. C. Crystal structure of the human class II protein HLA-DR1 complexed with an influenza virus peptide. Nature. 368:1994;215-221.
8. Jackson D. C., Brown L. E. A synthetic peptide of influenza virus hemagglutinin as a model antigen and immunogen. Pept. Res. 4:1991;114-124.
9. Rajnavölgyi É., Nagy Z., Kurucz I., Gogolák P., Tóth G. K., Váradi G., Penke B., Tigyi Z., Hollósi M., Gergely J. T cell recognition of the posttranslationally cleaved intersubunit region of influenza virus hemagglutinin. Mol. Immunol. 31:1994;1403-1414.
10. Nagy Z., Rajnavölgyi É., Hollósi M., Tóth G. K., Váradi G., Penke B., Tóth I., Horváth A., Gergely J., Kurucz I. The intersubunit region of the influenza virus hemagglutinin is recognized by antibodies during infection. Scand. J. Immunol. 40:1994;281-291.
11. Rajnavölgyi É., Horváth A., Gogolák P., Tóth G. K., Fazekas Gy., Fridkin M., Pecht I. Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites. Eur. J. Immunol. 27:1997;3105-3114.
12. Horváth A., Tóth G. K., Gogolák P., Nagy Z., Kurucz I., Pecht I., Rajnavölgyi É. A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Immunol. Lett. 60:1998;127-136.
13. Gogolák P., Réthi B., Horváth A., Tóth G. K., Cervenák L., László G., Rajnavölgyi É. Collaboration of TCR-, CD4- and CD28-mediated signaling in antigen-specific MHC class II-restricted T cells. Immunol. Lett. 54:1996;135-144.
14. Gogolák, P, Réthi, B, Horváth, A, and, Rajnavölgyi, É. Antigen presenting cell-induced fine tuning of murine helper T cell activation. Submitted.
15. Rötzschke O., Falk K. Origin, structure and motifs of naturally processed MHC class II ligands. Curr. Opin. Immunol. 6:1994;45-51.
16. Rajnavölgyi É., Simon Á., Nagy N., Dosztányi Zs., Simon I., Falk K. I., Klein E. A repetitive sequence of the Epstein-Barr virus nuclear antigen-6 encompasses overlapping regions which bind to various HLA-DR molecules. Bajusz S., Hudecz F. Peptides 1998. 1998;548-549 Akadémiai Kiadó Budapest.
17. Rajnavölgyi É., Nagy N., Thuresson B., Dosztányi Zs., Simon Á., Simon I., Karr R. W., Ernberg I., Klein E., Falk K. A repetitive sequence of EBV nuclear antigen 6 comprises overlapping T cell epitopes, which induce HLA-DR-restricted CD4+ T lymphocytes. Int. Immunol. 12:2000;281-293.
18. Merrifield R. B. The synthesis of a tetrapeptide. Solid phase peptide synthesis. J. Am. Chem. Soc. 85:1963;2149-2154.
19. Matsueda G. R., Stewart J. M. A p-methylbenzhydrylamine resin for improved solid-phase synthesis of peptide amides. Peptides. 2:1981;45-50.
20. Sakakibara S., Shimonishi Y., Kishida Y., Okada M., Sugihara K. Use of anhydrous hydrogen fluoride in peptide synthesis. I. Behavior of various protective groups in anhydrous hydrogen fluoride. Bull. Chem. Soc. Jpn. 40:1996;2164-2167.
21. Fremont D. H., Hendrickson W. A., Marrack P., Kappler J. Structures of an MHC class II molecule with covalently bound single peptides. Science. 272:1996;1001-1004.
22. Connolly M. L. Solvent-accessible surfaces of proteins and nucleic acids. Science. 221:1983;709-713.
23. Buus S. Description and prediction of peptide-MHC binding: The 'human MHC project'. Curr. Opin. Immunol. 11:1999;209-213.
24. Stern L. J., Wiley D. C. Antigenic peptide binding by class I and class II histocompatibility proteins. Structure. 2:1994;245-251.
25. Smith K. J., Reid S. W., Harlos K., McMichael A. J., Stuart D. I., Bell J. I., Jones E. Y. Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53. Immunity. 4:1996;215-228.
26. Chelvanayagam G., Apostolopoulos V., McKenzie F. C. Milestones in the molecular structure of the major histocompatibility complex. Protein Eng. 10:1997;471-474.
27. Teng M. K., Smolyar A., Tse A. G., Liu J. H., Hussey R. E., Nathenson S. G., Chang H. C., Reinherz E. L., Wang J. H. Identification of a common docking topology with substantial variation among different TCR-peptide-MHC complexes. Curr. Biol. 8:1998;409-412.
28. Willcox B. E., Gao G. F., Wyer J. R., Ladbury J. E., Bell J. I., Jakobsen B. K., van der Merwe P. A. TCR binding to peptide-MHC stabilizes a flexible recognition interface. Immunity. 10:1999;357-365.
29. Sant'Angelo D. B., Waterbury G., Preston-Hurlburt P., Yoon S. T., Medzhitov R., Hong S., Janeway C. A. Jr. The specificity and orientation of a TCR to its peptide-MHC class II ligands. Immunity. 4:1996;367-376.